Introduction
There are several reasons for developing animal models of human leukemia. The first is to assess the contribution of a genetic abnormality that is identified in a leukemia cell to the pathogenesis of the malignancy. The second is to investigate the pathophysiology of the leukemia in ways that would be difficult or impossible using primary human cells and cell lines. Finally, an accurate animal model of leukemia can serve as a platform for the development and evaluation of new treatments, including immune-based therapies.
Chronic myeloid or myelogenous leukemia (CML) is perhaps the best understood of all human malignancies. In part, this reflects identification of the Philadelphia chromosome over 40 years ago, and the subsequent isolation of the product of this translocation, the BCR/ABL oncogene. Fifteen years of intensive research demonstrated that the protein product of this gene, Bcr/Abl, was a dysregulated protein-tyrosine kinase that activated numerous intracellular signaling pathways and transformed fibroblasts and hematopoietic cells in culture. However, whether BCR/ABL was the principal cause of CML was in some doubt until the demonstration, a decade ago, that expression of this oncogene in mouse bone marrow induced a myeloproliferative illness closely resembling human CML [1, 2] . Recently, the central role of Bcr/Abl in human CML was confirmed by the astounding clinical efficacy of an inhibitor of the Abl tyrosine kinase, STI571. Having established BCR/ABL as the cause of CML, current work on models of CML centers on studying the pathophysiology of the leukemia and testing novel therapeutic strategies.
This article discusses recent progress in the development and use of models of CML, focusing on three distinct experimental approaches: xenotransplantation of primary human CML cells into immunodeficient mice and BCR/ ABL transgenic mice, and BCR/ABL retroviral bone marrow transduction/transplantation. With each method, emphasis is placed on what has been learned from the model, as well as the strengths and weaknesses of the system. The intention is to allow investigators considering the use of an animal model of CML to select the system that best fits their particular experimental requirements.
Xenotransplantation of Human CML Cells into Immunodeficient Mice

Engraftment of primary CML cells in SCID mice
Both normal and malignant human hematopoietic cells can engraft severe combined immunodeficient (SCID) and non-obese diabetic/LtSz/scid/scid (NOD/SCID) mice. Efficient engraftment of normal human myeloid cells in these mice requires concomitant administration of exogenous human cytokines, cotransplantation of marrow stroma or accessory cells, or use of large cell doses. Like most other established cell lines, cell lines derived from CML blast crisis patients efficiently engraft and disseminate in SCID mice [3, 4] . In contrast, attempts to propagate primary cells from CML patients were generally successful when the patients were in blast crisis [3, 5] , but stable engraftment of primary chronic-phase cells was not observed in early attempts [3, 6] .
Success was achieved by injecting very large cell inoculums (8-14 × 10 7 cells) from peripheral blood or marrow of chronic-phase CML patients into SCID mice [7] , resulting in engraftment of recipient bone marrow with human Models of chronic myeloid leukemia (CML) have proven invaluable for furthering our understanding of the molecular pathophysiology of this disease. Xenotransplantation of primary human CML cells into immunodeficient mice allows investigation into the nature of the most primitive repopulating cells in this leukemia, but the system is limited by variability and difficulty with experimental manipulation. Accordingly, a large effort has been invested in developing models of CML through expression of the BCR/ABL oncogene in the hematopoietic system of laboratory mice. Despite numerous attempts, an accurate transgenic mouse model of CML has not been produced, possibly because of the toxicity of BCR/ABL. Conditional transgenic mice are a promising new approach to this problem. A more successful strategy is retroviral transduction of BCR/ABL into mouse bone marrow in vitro, followed by transplantation into syngeneic or immunodeficient recipient mice. Recipients of marrow transduced with p210 BCR/ABL develop a fatal myeloproliferative illness that closely resembles human CML. This model is being used to define the signaling pathways required for leukemogenesis by BCR/ABL, and for developing new therapeutic approaches.
hematopoietic cells at levels from 1% to 10% within 30 to 60 days following injection. The degree of engraftment was cell dose-dependent, with very low engraftment observed at lower inoculums (1-4 × 10 7 cells). Human myeloid (CD13 + ), B-lymphoid (CD19 + ), and progenitor (CD34 + ) cells, as well as multilineage colony-forming cells were detected in recipient bone marrow, but there was no dissemination to peripheral blood, spleen, or other organs, nor did recipients develop any clinical illness. Surprisingly, treatment of recipients with exogenous human cytokines was not required for efficient engraftment, which may reflect aberrant production of cytokines by primitive CML progenitors [8] , with autocrine and paracrine effects after transplantation. Surprisingly, only about one third of CFC were derived from Ph + progenitors even when peripheral blood was used as the graft, demonstrating that primitive normal cells are mobilized in chronic-phase CML along with their malignant counterparts, and may engraft SCID mice more efficiently.
Superiority of NOD/SCID mice as recipients
Recently, three different laboratories [9•,10•,11•] have demonstrated that NOD/SCID mice are superior to SCID mice for engraftment of primary cells from chronic-phase CML patients. When injected with similar numbers of cells from chronic-phase patients, NOD/SCID recipients reproducibly had higher levels of human hematopoietic engraftment than SCID recipients [10•] . Eighty-four percent of mice receiving more than 4 × 10 7 cells showed evidence of engraftment, with half of these demonstrating greater than 10% human cells in their bone marrow (BM), assessed by human-specific and BCR/ABL-specific fluorescence in situ hybridization (FISH) [ [12] , but the relationship of this target cell to the engrafting cell in CML requires further study. Given the quantitative differences in engraftment of chronic, accelerated, and blast-phase cells [11•] , xenotransplantation may yield useful prognostic information when performed serially with samples from the same CML patient. The assay will also be useful for investigating the cellular biology of CML. For example, a recent study identified a subpopulation of quiescent primitive leukemia cells in chronic-phase CML patients that was nonetheless capable of engraftment of NOD/SCID mice [13] . Finally, the assay should be of use in testing new treatments, such as gene therapy approaches.
Limitations of the xenotransplant model system
Despite many advantages, the current xenotransplantation model has several problems that will limit its usefulness unless they can be overcome. First, engraftment appears to be extremely variable. 
BCR/ABL Transgenic Mice
Conventional BCR/ABL transgenic mice
In conventional transgenic mice, a BCR/ABL transgene is expressed under control of a promoter/enhancer element, integrates at a single chromosomal location, is present in one to several copies in a tandem repeat, and is found in all cells of the animal, including the germline. The expression of the transgene in the mice is predominantly controlled by the particular promoter/enhancer element utilized in the DNA construct. Usually, the transgene can be passed from a founder mouse to offspring, inherited in a Mendelian fashion. The different BCR/ABL transgenic mice that have been generated to date are listed in Table 1 .
The first BCR/ABL transgenic mice expressed a BCR/vabl facsimile oncogene (similar to p210 BCR/ABL) under the immunoglobulin heavy-chain enhancer (Eµ) or the widely expressed promoter/enhancer from the long terminal repeat (LTR) of the murine myeloproliferative sarcoma virus (MPSV) [15] . There was a decreased yield of transgenic offspring from eggs injected with either transgene DNA, but a small number of transgenic founders of both types, and some progeny developed clonal T and B lymphomas. More consistent success was achieved with express i o n o f B C R / A B L f r o m a s e g m e n t o f t h e m o u s e metallothionein (δMT-1) promoter, which is inducible with heavy metals but constitutively and widely expressed in transgenic mice. A δMT-1/p190 BCR/ABL transgene efficiently generated founders that developed leukemia with high frequency between 4 to 24 weeks of age [16, 17] . The malignant cells were positive for B220 (CD45R) and 6C3/ BP1 antigens, suggestive of an immature B-lymphoid cell phenotype. When the MT-1 promoter was used to generate p210 BCR/ABL transgenic mice, founders and progeny developed predominantly T-and B-cell leukemia/lymphoma, with a penetrance of about 60% by the age of 44 weeks [18, 19] . This disease pattern was significantly different from the δMT-1/p190 mice, which exhibit greater than 90% incidence of leukemia by 24 weeks and never develop T-cell disease [17, 20] . These results suggest that p210 BCR/ ABL has less potent and distinct lymphoid leukemogenic activity in transgenic mice when compared with p190.
These studies confirmed the leukemogenic activity of BCR/ABL in vivo, but none of the mice reproducibly developed myeloid leukemias or CML-like disease. The possible reasons for this are discussed herein. Recently, the p210 BCR/ABL gene has been expressed under control of the promoter of the tec gene, which encodes a cytoplasmic kinase preferentially expressed in the hematopoietic system [21•] . Five founders were obtained, two of which died of T-cell lymphoblastic leukemia between 3 and 4 months of age. One of these leukemic founders gave rise to a permanent line that showed no evidence of T-ALL but instead developed a slow myeloproliferative-like syndrome with 100% penetrance by 8 months of age. This syndrome was characterized by modestly increased peripheral blood leukocyte counts (9-15 × 10 3 /µL) composed predominantly of mature neutrophils, moderate thrombocytosis (80-200 × 104/µL), and mild anemia (hemoglobin 8.0-14.5 g/dL). Some mice became moribund at the age of around 1 year and showed infiltration of spleen and mesenteric lymph nodes with neutrophils, marked thrombocytosis, and severe anemia. BCR/ABL transgene expression was detected in circulating neutrophils by reverse transcriptase-polymerase-chain reaction (RT-PCR). This novel transgenic model is intriguing, but further studies are necessary to determine whether it represents an accurate model of CML. In particular, it is not clear whether the disease process is progressive or fatal in all offspring or if the illness is transplantable, and the cause of death in some mice appeared to be severe anemia, which is not a prominent feature of chronic-phase CML in human patients.
Conditional BCR/ABL transgenic mice
Recently, attention has turned to the use of conditional transgenic systems as an approach to developing a model of CML, based on the assumption that suppressing expression of a BCR/ABL transgene until after birth would prevent toxicity that might interfere with transgene expression. One type of binary transgene system utilizes the tetracycline-regulated transcriptional activator tTA. tTA is a fusion of the Escherichia coli tetracycline operon repressor and the herpesvirus transactivator VP16, which binds to tet operator DNA sequences and activates transcription in the absence of tetracycline, but not in its presence. In a recent study [22•] , four lines of "transresponder" transgenic mice with p210 BCR/ABL under control of the tetresponse element (TRE) were generated, and transgenic offspring were born with the expected Mendelian frequency and developed normally, indicating that the TREp210 transgene was not toxic. Transresponder mice were then mated to "transactivator" mice with tTA under control of the mouse mammary tumor virus long terminal repeat (MMTV-LTR) promoter/enhancer, known to express tTA in epithelial cells and bone marrow. Females were maintained on tetracycline beginning 5 days prior to mating to suppress expression of the BCR/ABL transgene. Double transgenic mice were obtained at the predicted Mendelian frequency and remained healthy as long as tetracycline administration was continued. Withdrawal of tetracycline resulted in development of fatal B-lymphoid leukemia with 100% incidence in all four lines. Surprisingly, readministration of tetracycline resulted in rapid disappearance of leukemic cells from blood and involved lymph nodes, with the majority of malignant lymphoblasts undergoing apoptosis [22• ]. These studies demonstrate that BCR/ABLinduced lymphoid leukemia is absolutely dependent on continued expression of the BCR/ABL oncogene, even at advanced stages of disease.
Embryonic stem-cell-based approaches to BCR/ABL expression in mice
A distinct approach to expression of BCR/ABL in mice is through the use of embryonic stem (ES) cells. The embryonic stem-cell system has principally been used to inactivate genes by homologous recombination ("knock-out"), but the potential also exists to introduce oncogenes, either as simple transgenes or by homologous recombination into the corresponding endogenous murine gene ("knockin"). ES cells can also be differentiated into multiple hematopoietic lineages in culture, allowing the opportunity to determine if oncogene expression might perturb hematopoietic development in vitro. Employing the knock-in approach, a p190 BCR/ABL transgene was created by homologous recombination in ES cells using a construct with fusion of mouse bcr exon 1 sequence with human BCR exon 1/ABL cDNA, with the resulting chimeric DNA expressed from the endogenous mouse bcr promoter [23] . Of 40 chimeric mice generated by blastocyst injection with the targeted ES cell clone, 38 developed B-lymphoid leukemia of the pre-B type by the age of 4 months. Other studies have examined the effect of BCR/ABL expression on hematopoietic differentiation of ES cells in vitro. Conditional expression (via the tet-regulatable system) of p210 BCR/ABL in ES cells stimulated multipotential progenitor expansion and myeloid lineage commitment [24•], whereas constitutive BCR/ABL expression in ES cells decreased the efficiency of embryoid body (EB) formation but increased the generation of myeloid hematopoietic progenitors in vitro [25] . More work is necessary to determine if these novel approaches will yield useful models of BCR/ABL-induced leukemia.
Applications of BCR/ABL transgenic mice
A great deal has been learned from BCR/ABL transgenic mice. These mice confirm that BCR/ABL can induce leukemia in vivo. The δMT-1-BCR/ABL transgenic mice express low levels of BCR/ABL in many tissues [17] , but only lymphoid leukemias develop, suggesting further that BCR/ABL is a leukemia-specific oncogene. With transgenic mice that can be maintained as a line, it is easy to generate more animals for study by breeding. This has facilitated studies of the karyotypic evolution of the B-lymphoid leukemia in p190 BCR/ABL transgenic mice [20] . The conditional BCR/ ABL transgenic mice will be particularly valuable for studying the earliest events in development of lymphoid leukemia and the mechanism of the anti-apoptotic action of BCR/ABL. It is also simple to breed a BCR/ABL transgene into different genetic backgrounds to test the role of other genes in leukemogenesis. This has allowed the demonstration that lymphoid leukemogenesis by p190 BCR/ABL does not require the normal bcr gene product [26] , whereas the tec-p210 transgenic mice rapidly develop T lymphomas rather than myeloproliferative disease in a p53 heterozygous background [27] . Although it is difficult, transgenic mice can be used to test the requirement of different functional domains of Bcr/Abl for leukemogenesis, and a recent study demonstrated that the C-terminal actin-binding domain was required for efficient development of lymphoid leukemia in mice [28] . Finally, BCR/ABL transgenic mice can be used for testing new therapies for Ph-positive leukemia, such as farnesyltransferase inhibitors [29] .
Limitations of BCR/ABL transgenic mice
Unfortunately, BCR/ABL transgenic mice have several disadvantages as a model system. The most significant drawback is that, despite over a decade of effort in generation of BCR/ ABL transgenic mice by conventional techniques, there is no transgenic mouse model of CML (with the possible exception of the tec/p210 BCR/ABL mice, which require further validation). The reasons for this are unclear, but the most plausible explanation may be lack of sufficient expression of the BCR/ABL transgene in myeloid and early progenitor/ stem cells, because retroviral expression of BCR/ABL in multipotent progenitor cells does induce CML-like disease in mice, as noted herein. Activated ABL genes are known to have cytotoxic effects, and the presence of the transgene in all tissues raises the possibility of toxicity during embryonic development. Toxicity was initially suggested by the inefficient generation of BCR/v-abl transgenic founders and the failure of this transgene to express prior to development of overt malignancy [15] , whereas a subsequent study directly confirmed that a BCR/ABL transgene expressed from the BCR promoter caused embryonic lethality [30] . The δMT-1 promoter should be expressed in myeloid progenitors, but this promoter may be downregulated in these transgenic mice because of transgene toxicity, and the resulting low levels of BCR/ABL expression are below a threshold required for oncogenic transformation by tyrosine kinases. This might explain the very low levels of bone marrow expression in young δMT-1/BCR/ABL transgenic mice, but much greater expression in the lymphoid leukemia cells [17] . In support of this hypothesis, when efforts were made to direct p210 BCR/ABL expression to myeloid cells by use of the CD11b or cathepsin G promoters, which are known to direct highlevel position-independent expression of reporter transgenes to myeloid cells, the p210 transgenic founders that were obtained neither expressed detectable levels of BCR/ ABL in their myeloid cells nor developed disease (Dziennis S, Van Etten RA, Tenen DG, Unpublished work; Pandolfi PP, Personal communication). Alternatively, it is possible that the bone marrow expression of these transgenes is heterogeneous and restricted to lymphoid progenitors. Table 2 . After considerable effort, a major breakthrough was achieved in 1990 when two groups were able to induce CML-like myeloproliferative disease and other hematologic malignancies in recipients of p210 BCR/ABL-transduced bone marrow [1, 2] . The CML-like leukemia was a fatal myeloproliferative disease arising 4 to 12 weeks following transplantation, characterized by peripheral blood leukocytosis with greatly increased neutrophils, and infiltration of spleen, liver, and lungs with maturing myeloid cells, leading to hepatosplenomegaly, and ultimately death from respiratory failure. Bone marrow of these mice exhibited myeloid hyperplasia with minimal fibrosis and less than 10% blasts. The myeloid cells express Bcr/Abl protein, contain increased levels of tyrosine phosphorylated proteins, and carry the retroviral provirus in chromosomal DNA, confirming that the disease was directly induced by BCR/ ABL. In addition to the CML-like disease, other recipients developed distinct hematopoietic malignancies, including B-lymphoid leukemia (similar to that observed in BCR/ABL transgenic mice), tumors of monocyte-macrophage lineage, and occasionally erythroleukemia and T-lymphoid leukemia [1, 2, 31] . The CML-like disease could be transferred to secondary recipients by transplantation of marrow, but with low efficiency [32, 33] . Some secondary recipients developed acute myeloid and lymphoid leukemia arising from the same provirally marked clone as the CML-like disease [32] , suggestive of disease progression to blast crisis.
These seminal studies established that BCR/ABL is the direct cause of CML, but the inefficiency of induction of CML-like disease made it difficult to use the model to study the pathophysiology of CML in mice. Using transient retroviral packaging systems to improve virus titer, several groups recently reported efficient induction of CML-like disease in mice by p210 BCR/ABL [34•,35•,36•] , where 100% of recipients of p210-transduced marrow succumbed to fatal CMLlike disease, identical to that described earlier, within 4 weeks after transplantation. The CML-like disease in these mice was polyclonal by provirus integration rather than the monoclonal pattern observed previously [1] , which confirmed increased transduction efficiency, and suggested that BCR/ ABL transduction alone was sufficient to induce the CML-like disease. However, because the number of transduced target cells received by each animal was not known, this could not be definitively established by these studies. The CML-like disease was efficiently transplanted from most, but not all, primary mice by transfer of bone marrow or spleen cells. Interestingly, only a small subset of the clones present in the primary mice contributed to day-12 spleen colonies [36•] and induced disease in secondary recipients [35•,36 •], suggesting heterogeneity between individual clones contributing to the expansion of myeloid cells in the primary animal, with only a minor subset capable of self-renewal as assessed by secondary transplantation. Did not observe CML-like disease in C57Bl/6 and DBA mouse strains [31] p210 CML, mast-cell disease, B/T-ALL Secondary transplantation of CML-like disease and clonally related acute myeloid and lymphoid leukemias [32] p190, p210 CML, B-ALL, macrophage disease p190 induced leukemias of shorter latency than p210 [48] p210 CML, B-ALL, macrophage disease, EL BCR/ABL-induced leukemias influenced by mouse strain and transduction conditions [37] p210 CML, B/T-ALL, macrophage disease
Efficient secondary transplantation of CML-like disease; heterogeneity of target cells [33] p210 CML, AML SCID mouse recipients; p53 +/+ donor marrow gave long latency MPD, whereas p53 -/-donors gave AML-like disease [49] p210 ⌬SH2 CML, AML SCID recipients; p210 SH2 mutants induced less aggressive CML/ AML-like disease *Disease phenotypes are defined in the text. AML-acute myeloid leukemia; B-ALL-B-cell acute lymphoblastic leukemia; CML-chronic myeloid leukemia; EL-erythroleukemia; GM-CSF-granulocyte-macrophage colony-stimulating factor; ICSBP-interferon consensus sequence binding protein; IL-interleukin; muts-mutations; SCID-severe combined immunodeficient; T-ALL-T-cell acute lymphoblastic leukemia.
Advantages and limitations of the retroviral transduction/transplantation model
Expression of BCR/ABL in vivo by retroviral transduction has a number of distinct advantages over transgenic mice. In this system, it is relatively easy to test different forms and mutants of BCR/ABL, simply by making new retroviral stocks. It is also easy, at least in principle, to test leukemogenicity of BCR/ABL in different genetic backgrounds and in mice with targeted mutations in different genes by employing mutant mice as donors and/or recipients in the system. The retroviral transduction system has been extended to the study of other leukemia oncogenes, although not all putative oncogenes induce leukemia in this system. Using simultaneous transduction of bone marrow with two distinct retroviruses, it is possible to observe synergistic interactions between two genes in leukemogenesis, but the relatively low incidence of cotransduction of stem cells with two viruses makes it implausible that dominant negative effects can be detected in such experiments. An alternative means to efficiently coexpress two genes is the use of retroviral vectors with the internal ribosome entry site (IRES) derived from encephalomyocarditis virus, which allows expression of two cistrons from the same proviral mRNA transcript. Coexpression of BCR/ABL with enhanced green fluorescent protein (eGFP) facilitates rapid titering of retroviral stocks and has been used to directly identify BCR/ABL-expressing cells in vivo [34•,35•] .However, the retroviral transduction/transplantation model has several disadvantages. The biggest drawback is that generation of diseased mice for study requires performing a new transduction/transplantation procedure, which is somewhat laborious. An additional concern is that BCR/ABL is expressed from the retroviral LTR in most of the vectors utilized, which obviously differs from the BCR promoter that expresses BCR/ABL in human CML. The LTR is probably a stronger promoter than BCR, possibly accounting for the short survival of mice with BCR/ABL-induced CML-like disease. As a consequence, the current system does not model the long latent period required for human CML patients to develop clinical symptoms following exposure to ionizing radiation. However, the short latency of murine CML-like disease may also reflect the requirement for stem cells to be cycling in order to be transduced by retroviral vectors, and the use of different vectors or transduction conditions may allow models of CML latency to be developed in mice [33] .
Studying the pathophysiology of CML using the retroviral transduction/transplantation model
The ability to induce CML-like disease in 100% of recipients of BCR/ABL-transduced marrow has allowed the system used as an actual assay for the first time to investigate the pathogenesis and pathophysiology of CML. One of the first uses of the efficient mouse model of CML was a comparison of the leukemogenic activity of the three principal forms of BCR/ABL: p190, p210, and p230. These oncogenes arise from different breakpoints on chromosome 22, generating three distinct fusion proteins that contain the same portion of c-Abl with different amounts of Bcr polypeptide sequence at the N-terminus and exhibit different intrinsic tyrosine kinase activity [36•] . In humans, the three forms of BCR/ABL are predominantly associated with distinct forms of leukemia [39] . The p210 form is of course found in chronic-phase CML, p190 is commonly observed in Ph-positive ALL but very rarely detected in CML, and p230 has been detected in several patients with a clinically mild variant of CML, chronic neutrophilic leukemia. These observations raise the question of whether different forms of BCR/ABL have intrinsically different leukemogenic activity in hematopoietic cells. The retroviral transduction/transplantation model offers an ideal system to compare the in vivo leukemogenic activity of these different BCR/ABL oncogenes after transduction of an identical spectrum of hematopoietic cells. All three forms of BCR/ABL were equally potent in induction of CML-like disease when marrow from donors treated with 5-FU was employed [36•] . There was no significant difference in survival, peripheral blood leukocyte counts, or spleen weights at death, suggesting that all three BCR/ABL oncogenes induced a similar proliferative stimulus to myeloid cells under these conditions. These results do not support the hypothesis that p230 induces a distinct and less aggressive form of CML, and suggest that the rarity of p190 in chronic-phase CML may reflect infrequent BCR intron 1 breakpoints during the genesis of the Ph chromosome in stem cells, rather than intrinsic differences in myeloid leukemogenicity between p190 and p210.
The retroviral transduction/transplantation CML model can also be used to identify and validate the signaling pathways activated by BCR/ABL that are critical to leukemogenesis. It is already clear that results of in vitro studies of BCR/ABL signaling and transformation frequently do not correlate with leukemogenesis. Despite cell culture studies that suggested a role for the SH3 domain of Bcr/Abl in leukemogenicity [40] , SH3 can be deleted from p210 Bcr/Abl with no effect on induction of CML-like disease in vivo [41] . In contrast, the p210 Bcr/Abl Y177F point mutant that cannot bind the Grb2 adapter protein is profoundly defective for induction of CML-like disease in mice, with recipients instead developing B-lymphoid leukemia or a novel T-cell lymphoma [42•] . This result resolves a long-standing controversy over the importance of direct binding of Grb2 to Bcr/Abl for leukemogenesis [43] , and validates the Grb2 pathway as an important target for rational drug design in CML. The SH2 domain is not required for induction of B-lymphoid leukemia by BCR/ABL [38] , but it contributes to efficient induction of CML-like disease in mice [38, 44] . Although the SH2 domain of Bcr/Abl was initially reported to be required for activation of the phosphatidylinositol 3-kinase (PI 3-K) pathway in hematopoietic cells [44] , subsequent studies found no defect in PI 3-K activation in cells transduced with BCR/ABL SH2 mutants [38] , and the mechanism of the modest defect in induction of CML-like disease by these mutants requires further study. The model system can also be employed to determine the role of other genes in leukemogenesis by BCR/ABL, by employing mice with naturally occurring or targeted mutations in these genes as donors and/or recipients. BCR/ABL induces constitutive activation of STAT5 in hematopoietic cells, but studies in Stat5a/b-deficient mice demonstrate that STAT5 is not absolutely required for induction of CML-like disease in mice [45•] . Recently, aberrant transcripts for interleukin 3 (IL-3) and granulocyte-colony stimulating factor (G-CSF) have been identified in primitive Ph-positive human CML progenitors that may account in part for the autonomous in vitro growth of these cells [8] . Interestingly, increased plasma levels of IL-3 [35•,36 •] and granulocyte macrophage colony stimulating factor (GM-CSF) [35•] have been detected in plasma of mice with BCR/ABL-induced CMLlike disease. The Il3 and Gmcsf genes have been deleted in mice through homologous recombination, and neither gene is required in donor or recipient for efficient induction of CML-like disease by p210 BCR/ABL [46] . These examples illustrate how this CML model system can provide important new knowledge about the pathogenesis of CML that would be difficult or impossible to obtain from studies of human patients or primary human CML cells. However, continued correlative studies between human CML and the murine CML-like disease are necessary, and conclusions reached in the mouse model system require validation, if possible, in human CML patients and cells.
Conclusions
It is apparent that we have learned an enormous amount about chronic myeloid leukemia in the recent past, and one could argue fairly convincingly that it is the best understood of all human malignant disorders. In no small part, this is because of what has been learned from animal models of the disease. The power of animal model systems derives from their ability to accurately recapitulate the complex physiology of CML in vivo. This suggests that the most productive future applications of these model systems will be in areas related to therapy of CML that are controversial today, such as identifying signaling pathways whose inhibition might complement Abl kinase inhibitor therapy, and mechanisms of graft-versus-leukemia effects. Critical advances in these areas will be facilitated by the careful and creative application of the animal model systems described in this review.
